The rationale for implementing insulin prophylaxis therapy to prevent type 1 diabetes in humans was based ... with other inbred strains carrying gene mutations for physical mapping/positional ...

The first human trial of insulin-producing cells that have been gene-edited to evade immune ... being injected into a 42-year-old man with type 1 diabetes early in December. As a precaution ...

Additionally, the company is progressing with its diabetes gene therapy program ... as well as developing gene therapies for Type 1 and Type 2 diabetes in collaboration with the University ...

Smith, a 35-year-old nurse from London, Ontario, has Type 1 diabetes ... presented at an American Diabetes Association ...

Fractyl Health is cutting nearly a fifth of its workforce as it streamlines resources and shifts focus toward certain ...

Diabetes develops when the body fails to manage its blood glucose levels. One form of diabetes causes the body to not produce insulin at all. Called Type 1 diabetes, or T1D, this autoimmune diseas ...

Just over a year after its first phase 3 trial of its Engensis gene therapy for painful diabetic ... is likely to become even more prevalent as diabetes is becoming more common around the world.

"Multiple innovations have improved automated insulin delivery systems, which constitute the most advanced therapy for type 1 diabetes. For that reason, the placebo intervention, which consisted ...

Kate Therapeutics' pipeline is still in the preclinical stage of development but includes candidates for DMD, facioscapulohumeral dystrophy (FSHD), and myotonic dystrophy type 1 (DM1), as well as ...